The Health Law attorneys at Wilentz, Goldman & Spitzer, P.A. offer deep experience across a range of healthcare needs, with strong capabilities in all aspects of strategy and operations, regulatory counseling, healthcare financing and transactions.
We provide advice relating to cutting-edge legal issues facing health law participants, representation in connection with entity formation, strategic transactions and guidance on the complex regulatory and operational landscape facing those conducting business in the healthcare sector. Our practice earns high rankings across peer review publications, including Chambers USA, which in 2021 ranks Wilentz among the top two healthcare practices in New Jersey, based in part on client and other sources who laud the Wilentz team as "extremely knowledgeable" and "always looking out for our best interest with honesty and integrity," and "They listened to my concerns and addressed them, came prepared to meetings and were very responsive to my questions and calls.”
We represent a broad range of healthcare providers and our team serves as general counsel to dozens of healthcare entities, from individual healthcare practitioners to whole healthcare systems. Our lawyers have practiced at the forefront of healthcare law for decades, advising on a variety of emerging developments in health law, such as telemedicine, and Clinically Integrated Networks (“CINs”). Wilentz's prominence in the health sector is based on both our knowledge of the law impacting our healthcare clients and our in depth understanding of the commercial, regulatory and operational issues involved in building and growing successful healthcare businesses.
We represent physicians, dentists and other healthcare providers and entities on the formation and structure of their practice and in connection with joint ventures, corporations, partnerships and limited liability companies. We handle all aspects of sales, purchases, mergers and acquisitions of healthcare entities, and related licensure issues.
We also represent private equity and venture capital funds in connection with acquisitions, dispositions, joint ventures and investment opportunities in health related entities.